| Literature DB >> 35956419 |
Ali Mahmoudi1, Stephen L Atkin2, Nikita G Nikiforov3, Amirhossein Sahebkar4,5,6.
Abstract
BACKGROUND: Diabetes is an increasingly prevalent global disease caused by the impairment in insulin production or insulin function. Diabetes in the long term causes both microvascular and macrovascular complications that may result in retinopathy, nephropathy, neuropathy, peripheral arterial disease, atherosclerotic cardiovascular disease, and cerebrovascular disease. Considerable effort has been expended looking at the numerous genes and pathways to explain the mechanisms leading to diabetes-related complications. Curcumin is a traditional medicine with several properties such as being antioxidant, anti-inflammatory, anti-cancer, and anti-microbial, which may have utility for treating diabetes complications. This study, based on the system biology approach, aimed to investigate the effect of curcumin on critical genes and pathways related to diabetes.Entities:
Keywords: DGIdb; DisGeNET; KEGG; STITCH; curcumin; diabetes; gene ontology
Mesh:
Substances:
Year: 2022 PMID: 35956419 PMCID: PMC9370108 DOI: 10.3390/nu14153244
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1An overview of an investigative process undertaken in the present study. This investigation is organized into three sections: (Step 1) exploring the gene/protein target of curcumin and diabetes in different databases. (Step 2) Analyzing two data sets of curcumin targets and diabetes-related genes/proteins and discovering the associations. (Step 3) Probing the pathways and biological process, and gene-disease enrichment analysis related to obtained important intersection protein/genes, and then validation with a literature review.
Important hub genes associated with diabetes.
| Gene Symbol | Gene Full Name | Protein Class | DSI g | Score GDA | Network Analyser | ||
|---|---|---|---|---|---|---|---|
| Degree | Betweenness | Closeness | |||||
| INS | Insulin | Plasma proteins | 0.445 | 0.70 | 78 | 0.2223 | 0.5201 |
| TP53 | Tumour protein p53 | Transcription factors | 0.236 | 0.50 | 48 | 0.0746 | 0.4714 |
| EGFR | Epidermal growth factor receptor | Enzymes | 0.295 | 0.37 | 50 | 0.0632 | 0.4669 |
| STAT3 | Signal transducer and activator of transcription 3 | Transcription factors | 0.320 | 0.35 | 61 | 0.0604 | 0.4752 |
| TNF | Tumour necrosis factor | Plasma proteins | 0.231 | 0.50 | 60 | 0.0451 | 0.4845 |
| PPARG | Peroxisome proliferator-activated receptor gamma | Nuclear receptors | 0.358 | 0.50 | 35 | 0.0411 | 0.4506 |
| ALB | Albumin | Plasma proteins | 0.317 | 0.60 | 47 | 0.0406 | 0.4655 |
| CAV1 | Caveolin 1 | Transporters | 0.388 | 0.50 | 38 | 0.0387 | 0.4534 |
| RELA | RELA proto-oncogene, NF-kB subunit | Transcription factors | 0.406 | 0.50 | 36 | 0.0338 | 0.4291 |
| IL6 | Interleukin 6 | Plasma proteins | 0.248 | 0.50 | 58 | 0.0302 | 0.4744 |
| CASP3 | Caspase 3 | Enzymes | 0.351 | 0.50 | 37 | 0.0295 | 0.4439 |
| VEGFA | Vascular endothelial growth factor A | Plasma proteins | 0.266 | 0.50 | 41 | 0.0237 | 0.4562 |
| NOS3 | Nitric oxide synthase 3 | Enzymes | 0.378 | 0.40 | 30 | 0.0349 | 0.4400 |
| PPARA | Peroxisome proliferator activated receptor alpha | Nuclear receptors | 0.432 | 0.30 | 25 | 0.0337 | 0.4267 |
| FN1 | Fibronectin 1 | Plasma proteins | 0.365 | 0.40 | 35 | 0.0233 | 0.4273 |
Figure 2Illustrating critical diabetic disease PPI network based on principal centralities (Degree and Betweenness) using Cytoscape software. The entire PPI network was identified with 298 nodes and 1651 edges. The larger the node size indicates, the higher the Degree, and the higher intensity in node color indicates higher Betweenness in the PPI network.
Figure 3Three top clusters of the PPI network are constructed with important genes related to diabetes based on MCODE analyses. The specification of each MCODE containing MCODE1) Score: 10.22, Seed: TIMP1, Node: 19 Edge: 92. MCODE2) Score: 7.09, Seed: FGF2 Node: 12, Edge: 39. MCODE3) Score: 5.06, Seed: TNFRSF1A Node: 33, Edge: 81. The larger node size indicates a higher degree, and the higher intensity in node color indicates a higher MCODE score in the MCODE analysis.
Figure 4Intersection analysis to determine shared proteins between curcumin and curated genes related to diabetes using the Venn diagram: (A) All genes and (B) Hub genes.
The hub genes of the diabetes PPI network that are the targets of curcumin.
| Shared Protein Targets | STITCH-Score | Action |
|---|---|---|
| TP53 | 0.962 | Activation/inhibition |
| EGFR | 0.987 | inhibition |
| STAT3 | 0.959 | inhibition |
| PPARG | 0.957 | Activation |
| IL6 | 0.869 | inhibition |
| CASP3 | 0.959 | Activation/inhibition |
| VEGFA | 0.868 | inhibition |
| NOS3 | 0.820 | Activation/inhibition |
| PPARA | 0.866 | Activation |
| FN1 | 0.844 | inhibition |
Figure 5Intersection analysis to determine shared proteins between curcumin and the clusters of PPI network-related genes to diabetes based on MCODEs analysis.
Figure 6The nine highest adjusted p-value signaling pathways were achieved by KEGG enrichment analyses of 35 shared proteins (All genes associated with diabetes ∩ curcumin targets) using the Enrichr algorithm.
Figure 7Gene ontology enrichment analysis of 35 shared protein targets (All genes associated with diabetes ∩ curcumin targets) using the Enrichr algorithm. (A) Ten highest adjusted p-value Biological process; (B) Ten highest adjusted p-value Cellular compound; (C) Ten highest adjusted p-value Molecular function.
Enrichment analysis of 35 shared genes through diverse gene association diseases databases based on Enrichr algorithm for diabetic diseases.
| Jensen Diseases | ||
|---|---|---|
| Diseases | Adj. | Gene Name |
| Diabetic retinopathy | 8.32 × 10−8 | IL6; NOS3; AKR1B1; ICAM1; VEGFA |
| Diabetes mellitus (1,2) | 5.67 × 10−5 | LEP; STAT3; PPARG; SLC2A4 |
| Type 2 diabetes mellitus | 0.027 | IL1B; PPARG; VEGFA |
| GWAS Catalog | ||
| Type 2 diabetes | 0.01278 | LEP; STAT3; PPARG; VEGFA; BCL2 |
| DisGeNET | ||
| Diseases | Adj. | Gene Name |
| Diabetes Mellitus, Non-Insulin-Dependent | 2.33 × 10−31 | CDKN1A; AKR1B1; SLC2A4; PTGS2; HIF1A; EGFR; ICAM1; CASP3; HMOX1; CCL2; |
| Diabetes Mellitus, Insulin-Dependent | 1.56 × 10−27 | AKR1B1; SLC2A4; PTGS2; EGFR; ICAM1; CASP3; HMOX1; CCL2; GSTM1; NOS2; NOS3; |
| Diabetic Nephropathy | 1.73 × 10−29 | CDKN1A; AKR1B1; PTGS2; HIF1A; THBS1; EGFR; ICAM1; CCL2; GSTM1; |
| Diabetic Retinopathy | 5.79 × 10−26 | GSTM1; NOS2; NOS3; MMP2; FN1; AKR1B1; PTGS2; HIF1A; THBS1; MMP9; |
| Gestational Diabetes | 2.02 × 10−12 | AR; IL6; NOS3; IL1B; LEP; CCL2; PPARG; VEGFA |
| Prediabetes syndrome | 5.82 × 10−9 | IL6; IAPP; PPARG; SLC2A4; TP53; TLR4 |
| Brittle diabetes | 1.54 × 10−4 | NOS3; DDIT3; STAT3 |
| OMIM Disease | ||
| Diseases | Adj. | Gene Name |
| diabetes mellitus, type 2 | 0.567 × 10−3 | SLC2A4; PPARG |
| Rare Diseases GeneRIF ARCHS4 Predictions | ||
| Diseases | Adj. | Gene Name |
| Diabetic mastopathy | 5.515 × 10−6 | STAT3; IL6; IL1B; TLR4; NFE2L2; PTGS2 |
| Rare Diseases AutoRIF Gene Lists | ||
| Diseases | Adj. | Gene Name |
| Insulin-resistance type B | 4.197 × 10−28 | NOS2; NOS3; STAT3; SLC2A4; PTGS2; EGFR; ICAM1; IL6; CASP3; IL1B; |
| Diabetic mastopathy | 1.58 × 10−22 | CDKN1A; STAT3; AKR1B1; FOXO3; PTGS2; HIF1A; THBS1; MMP9; ICAM1; |
| Nephrogenic diabetes insipidus | 2.45 × 10−5 | NOS2; NOS3; PTGS2; EGFR; NFE2L2 |
| Cardiomyopathy diabetes deafness | 6.12 × 10−4 | NOS3; HMOX1 |
| Maturity-onset diabetes of the young | 9.82 × 10−4 | CASP3; IAPP; PPARG |
| Neurogenic diabetes insipidus | 0.006854232 | CASP3; PTGS2 |